Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions

Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage II Adult T-cell Leukemia/Lymphoma | Stage II Childhood Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Stage III Adult T-cell Leukemia/Lymphoma | Stage III Childhood Lymphoblastic Lymphoma | Stage IV Adult Lymphoblastic Lymphoma | Stage IV Adult T-cell Leukemia/Lymphoma | Stage IV Childhood Lymphoblastic Lymphoma | T-cell Adult Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

What is the purpose of this trial?

This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.



Participation Guidelines

Age:
1 Year - 30 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
January 2007
Last Updated:
May 19, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00408005